Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned.  ...

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...

In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now ...

This week, a Watertown biotech secured a $185 million private placement, Curie.Bio landed a new seed fund and Airna is hiring ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

News of the layoffs come just one day after the company reported a 5% year over year revenue increase — boosting revenue to ...

Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a ...

Stakeholders from different industries convened to discuss the roadmap ahead to become the next innovation powerhouse at ...

The Crimson spoke to a range of commercial realtors, startup founders, and a commercial lab space owner to understand how the immense draw of Kendall Square has forced the myriad startup companies ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

A majority of U.S. senators and representatives receive campaign funding from pharmaceutical companies — an important part of ...

Fresh from FDA approval for its paediatric stem-cell product, Mesoblast is pursuing consent for indications of heart disease ...